Be­hind gener­ic drug short­ages, House com­mit­tee points to lack­lus­ter man­u­fac­tur­ing and high prices

The see­saw be­tween ques­tion­able gener­ic drug man­u­fac­tur­ing and rock bot­tom prices took the spot­light at a House Ways and Means Com­mit­tee hear­ing on chron­ic drug short­ages Tues­day morn­ing.

“Poor man­u­fac­tur­ing qual­i­ty is the lead­ing dri­ver of chron­ic short­ages and it’s the most pre­ventable,” Com­mit­tee Chair Ja­son Smith (R-MO) said at the start of the hear­ing. The com­mit­tee turned to six ex­perts from in­dus­try and acad­e­mia to un­der­stand po­ten­tial so­lu­tions.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER